GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (FRA:RDDA) » Definitions » Debt-to-EBITDA

Dr Reddy's Laboratories (FRA:RDDA) Debt-to-EBITDA : 0.22 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Dr Reddy's Laboratories Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dr Reddy's Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €151 Mil. Dr Reddy's Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €68 Mil. Dr Reddy's Laboratories's annualized EBITDA for the quarter that ended in Dec. 2023 was €988 Mil. Dr Reddy's Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.22.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Dr Reddy's Laboratories's Debt-to-EBITDA or its related term are showing as below:

FRA:RDDA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.18   Med: 0.98   Max: 1.89
Current: 0.23

During the past 13 years, the highest Debt-to-EBITDA Ratio of Dr Reddy's Laboratories was 1.89. The lowest was 0.18. And the median was 0.98.

FRA:RDDA's Debt-to-EBITDA is ranked better than
80.45% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs FRA:RDDA: 0.23

Dr Reddy's Laboratories Debt-to-EBITDA Historical Data

The historical data trend for Dr Reddy's Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Debt-to-EBITDA Chart

Dr Reddy's Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.08 0.70 0.75 0.75 0.18

Dr Reddy's Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.20 0.14 0.14 0.22

Competitive Comparison of Dr Reddy's Laboratories's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dr Reddy's Laboratories's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's Debt-to-EBITDA falls into.



Dr Reddy's Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dr Reddy's Laboratories's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(138.443 + 14.51) / 845.041
=0.18

Dr Reddy's Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(150.887 + 67.761) / 987.824
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Dr Reddy's Laboratories  (FRA:RDDA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Dr Reddy's Laboratories Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Dr Reddy's Laboratories (FRA:RDDA) Business Description

Address
8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories (FRA:RDDA) Headlines

No Headlines